Difference between revisions of "Team:ETH Zurich/Collaborations"
| Line 7: | Line 7: | ||
<h2><a href="https://2015.igem.org/Team:Amoy#">Amoy</a></h2> | <h2><a href="https://2015.igem.org/Team:Amoy#">Amoy</a></h2> | ||
| − | <p>We collaborated with Amoy team | + | <p>We collaborated with Amoy team by contributing to their newsletter. We have written about the selection process for iGEM in the <a href="http://issuu.com/amoy-igem/docs/2015newsletterno1?e=17843433/13214508">No1 issue</a> and participated in the questionnaire about the most useful software for us in <a href="http://issuu.com/amoy-igem/docs/2015-newsletter-no.6">No6 issue</a>. |
We also published a description of our project in <a href="http://issuu.com/amoy-igem/docs/2015newsletter-3">No3 issue</a>, an update in <a href="http://issuu.com/amoy-igem/docs/2015newsletterno5">issue No5</a> and abour our human practices in <a href="http://issuu.com/amoy-igem/docs/2015-newsletter-no.7">issue No7</a>. | We also published a description of our project in <a href="http://issuu.com/amoy-igem/docs/2015newsletter-3">No3 issue</a>, an update in <a href="http://issuu.com/amoy-igem/docs/2015newsletterno5">issue No5</a> and abour our human practices in <a href="http://issuu.com/amoy-igem/docs/2015-newsletter-no.7">issue No7</a>. | ||
Finally, we made a short assay about the situation of synthetic biology in Switzerland for the <a href="http://issuu.com/amoy-igem/docs/2015newsletterno4">Special issue</a> and about the ethical dilemmas of editing a human embryo for the <a href="http://issuu.com/amoy-igem/docs/2015newsletterno2?e=17843433/13214519">No2 issue</a>. </p> | Finally, we made a short assay about the situation of synthetic biology in Switzerland for the <a href="http://issuu.com/amoy-igem/docs/2015newsletterno4">Special issue</a> and about the ethical dilemmas of editing a human embryo for the <a href="http://issuu.com/amoy-igem/docs/2015newsletterno2?e=17843433/13214519">No2 issue</a>. </p> | ||
| Line 19: | Line 19: | ||
<h2><a href="https://2015.igem.org/Team:Stockholm">Stockholm</a></h2> | <h2><a href="https://2015.igem.org/Team:Stockholm">Stockholm</a></h2> | ||
| − | <p> | + | |
| + | <p>Starting from the very beginning of our iGEM summer we were in continuous contact with the team from Stockholm. We realized soon that our projects were going into a similar direction, both focusing on cancer detection in samples of bodily fluids, using engineered bacteria that will bind to cancer cells. In contrast to our project, Stockholm’s ABBBA is focussed on the detection of one specific type of cancer at a time. In several Skype meetings we exchanged our ideas about the best possible setup for single cell analysis and signal integration of the bacteria upon binding to a cancer cell. We provided the team from Stockholm with inputs on microfluidics as a setup for the final analysis and they helped us when we were struggling with the recovery of our gene fragments.</p> | ||
| + | |||
| + | <h3>Validation of binding to cancer cells</h3> | ||
| + | <h3>Characterization of lldR-operator promoter collection</h3> | ||
| + | |||
| + | |||
</html> | </html> | ||
Revision as of 14:28, 5 September 2015
- Project
- Modeling
- Lab
- Human
Practices - Parts
- About Us
Collaborations
Amoy
We collaborated with Amoy team by contributing to their newsletter. We have written about the selection process for iGEM in the No1 issue and participated in the questionnaire about the most useful software for us in No6 issue. We also published a description of our project in No3 issue, an update in issue No5 and abour our human practices in issue No7. Finally, we made a short assay about the situation of synthetic biology in Switzerland for the Special issue and about the ethical dilemmas of editing a human embryo for the No2 issue.
Darmstadt
We helped Darmstadt to evaluate their software.
EPFL
EPF Lausanne and ETH Zurich asked together people from the street about their opinions in synthetic biology
Stockholm
Starting from the very beginning of our iGEM summer we were in continuous contact with the team from Stockholm. We realized soon that our projects were going into a similar direction, both focusing on cancer detection in samples of bodily fluids, using engineered bacteria that will bind to cancer cells. In contrast to our project, Stockholm’s ABBBA is focussed on the detection of one specific type of cancer at a time. In several Skype meetings we exchanged our ideas about the best possible setup for single cell analysis and signal integration of the bacteria upon binding to a cancer cell. We provided the team from Stockholm with inputs on microfluidics as a setup for the final analysis and they helped us when we were struggling with the recovery of our gene fragments.